Add
AUXL to Portfolio
Set Alert
Email to a
Friend
| |||
|
|
Quotes & Info
|
| AUXL > SEC Filings for AUXL > Form 8-K on 1-Oct-2009 | All Recent SEC Filings |
1-Oct-2009
Regulation FD Disclosure, Other Events, Financial Statements and Exh
On October 1, 2009, Auxilium Pharmaceuticals, Inc. ("Auxilium") issued a press release announcing the closing of its previously announced public offering of 3,000,000 shares of Auxilium common stock. Prior to the closing of the offering, Jefferies & Company, Inc., acting as the sole book-running manager of the offering, exercised in full its over-allotment option to purchase an additional 450,000 shares of Auxilium common stock. The exercise of this option increased the size of the offering to an aggregate of 3,450,000 shares of Auxilium common stock.
A copy of Auxilium's press release announcing the closing of the offering is being furnished with this Report as Exhibit 99.1 and is incorporated herein by reference.
In accordance with General Instruction B.2 of Form 8-K, the information set forth in this Item 7.01, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
On September 30, 2009, Auxilium consummated the closing of its previously announced public offering of 3,000,000 shares of Auxilium common stock. Prior to the closing of the offering, Jefferies & Company, Inc., acting as the sole book-running manager of the offering, exercised in full its over-allotment option to purchase an additional 450,000 shares of Auxilium common stock. The exercise of this option increased the size of the offering to an aggregate of 3,450,000 shares of Auxilium common stock. Auxilium received proceeds, net of offering expenses and underwriting discounts and commissions, of approximately $115.7 million from the offering.
(d) Exhibits.
Exhibit No. Description of Exhibit
99.1 Press release of Auxilium Pharmaceuticals, Inc. dated October 1, 2009.
|
|